Drug Trial Radar · NCT05686044
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Apr 1, 2023
Primary completion
Feb 13, 2024
Study completion Feb 13, 2024
Sponsor
- Lead sponsor
- Annovis Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure efficacy and safety of three different doses of buntanetap/Posiphen compared with placebo in participants with mild to moderate Alzheimer's disease. Study details include: The double-blind treatment duration will include a screening period of up to 42 days followed by 12 weeks of treatment at home. The study duration will be 4-5 months. There will be 4 in-clinic visits and 1 phone call.
Conditions
- Alzheimer Disease
Interventions
Buntanetap/PosiphenDrug
HPMC (vegetarian source) capsule shells
PlaceboDrug
HPMC (vegetarian source) capsule shells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in ADAS-Cog11Time frame: Baseline to the end of treatment period (12 weeks)
- ADCS-CGIC at Week 12Time frame: Baseline to the end of treatment period (12 weeks)
Locations
54 sites in 1 country. Site status is shown where the registry gives one.
CCT Research - Gilbert Neurology Partners
Gilbert, Arizona
CCT Research - Foothills Center
Phoenix, Arizona
The Belinga Clinic
Fort Smith, Arkansas
Sun Valley Research Center
Imperial, California
CenExel Clinical Clinical Research, Inc
Los Alamitos, California
Cenexel Rocky Mountain Clinical Research
Englewood, Colorado
Ki Health Partners LLC D/B/A New England Institute for Clinical Research
Stamford, Connecticut
Visionary Investigators Network
Aventura, Florida
K2 Medical Research
Clermont, Florida
The Neurology Institute - Coral Springs
Coral Springs, Florida
JY Research Inst.
Cutler Bay, Florida
Arrow Clinical trial
Daytona Beach, Florida
Accel Research Sites - DeLand Clinical Research Unit
DeLand, Florida
New Life Medical Research Center
Hialeah, Florida
CenExel RCA
Hollywood, Florida
Coral Clinic Reserach LLC
Homestead, Florida
Charter Research
Lady Lake, Florida
ClinCloud, LLC
Maitland, Florida
K2 Medical Research
Maitland, Florida
Merritt Island Clinical Research LLC
Merritt Island, Florida
Premier Clinical Research Institute, Inc
Miami, Florida
Gold Coast Health Research, LLC
Miami, Florida
Medical Professional Clinical Research Center, Inc
Miami, Florida
Reliant Medical Research
Miami, Florida
Ezy Medical Research Co.
Miami, Florida
Nuovida Research Center
Miami, Florida
Renstar Medical Research
Ocala, Florida
Visionary Investigators Network
Pembroke Pines, Florida
Napa Research
Pompano Beach, Florida
K2 Medical Research
Tampa, Florida
K2 Summit Research
The Villages, Florida
ClinCloud, LLC
Viera, Florida
Conquest Research, LLC
Winter Park, Florida
Charter Research
Winter Park, Florida
CenExel iResearch, LLC
Decatur, Georgia
Center for Advanced Research & Education
Gainesville, Georgia
Hawaii Pacific Neuroscience, LLC
Honolulu, Hawaii
Southern Illinois University School of Medicine
Springfield, Illinois
Josephson Wallack Munshower Neurology, P.C.
Indianapolis, Indiana
Northern Light Acadia Hospital
Bangor, Maine
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.